BIIB34:BVMF
Biogen Inc BDR
R$ १८४.४९
०.००%
(०.००) 1D
अक्टोबर ५, १५:५९:१३ GMT-३ · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
३२.३९ अरब
Avg. vol.
७.००
Volume
०.००
52-wk high
R$ १९१.००
52-wk low
R$ १२८.६९
Shares outstanding
१४.७८ करोड
No. of employees
८ हजार
Mkt. cap
३२.३९ अरब
Avg. vol.
७.००
Volume
०.००
52-wk high
R$ १९१.००
52-wk low
R$ १२८.६९
Shares outstanding
१४.७८ करोड
No. of employees
८ हजार
News stories
From web sources and news partners
Pluang
·
३ घण्टा पहिले
Biogen expected to slightly beat Q3 earnings wi...
Yahoo Finance
·
५ घण्टा पहिले
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
AD HOC NEWS
·
१४ घण्टा पहिले
Biogen reports lupus data while Biogen stock trades at EUR 199.33
Kalkine Media
·
१ दिन पहिले
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees७.५ हजार
Founded१९७८
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websitebiogen.com